|Title:||Methods and compositions for the treatment of gastrointestinal disorders|
|Abstract:|| The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.|
|Inventor(s):|| Currie; Mark (Sterling, MA), Mahajan-Miklos; Shalina (Stanford, CA), Milne; G. Todd (Brookline, MA), Norman; Thea (Cambridge, MA) |
|Assignee:|| Ironwood Pharmaceuticals, Inc. (Cambridge, MA) |
|Filing Date:||Apr 05, 2010|
|Claims:||1. A peptide consisting of the amino acid sequence Cys.sub.6 Cys.sub.7 Glu.sub.8 Tyr.sub.9 Cys.sub.10 Cys.sub.11 Asn.sub.12 Pro.sub.13 Ala.sub.14 Cys.sub.15 Thr.sub.16 Gly.sub.17 Cys.sub.18 Tyr.sub.19 (SEQ ID NO: 31), wherein disulfide bonds are present between Cys.sub.6-Cys.sub.11, Cys.sub.7-Cys.sub.15, and Cys.sub.10-Cys.sub.18. |
2. A pharmaceutical composition comprising the peptide of claim 1 and a pharmaceutically acceptable carrier or excipient.